Apr 16, 2020

Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)

Leading biotech industry portal BioSpace covered Starpharma’s finding that its proprietary dendrimer SPL7013 showed significant activity against  SARS-CoV-2, the coronavirus that causes COVID-19. It noted Starpharma will evaluate product concepts and formulation options for SPL7013 which may have potential applications in the prevention and management of COVID-19.

To read the full article, click here

 This contains certain forward-looking statements.